Physician profile
Daniel Sanchez
NPI 1366435190
$5,766.67
in general payments reported to CMS, 2019-2025
34 companies · $884 in 2025
The $884 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $558 · 2021: $1,006 · 2022: $891 · 2023: $869 · 2024: $309 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,061.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $960.72 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $746.92 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $673.56 | 2021-2025 | Jardiance, Tradjenta |
| Novo Nordisk INC | $554.51 | 2019-2023 | Rybelsus, Ozempic, Tresiba |
| Bayer Healthcare Pharmaceuticals INC. | $454.14 | 2021-2024 | |
| Glaxosmithkline, LLC. | $348.26 | 2021-2025 | Arexvy, Shingrix, Flulaval Quadrivalent |
| Valeritas, INC. | $307.56 | 2019 | |
| Amgen INC. | $262.30 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Lilly USA, LLC | $231.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $166.20 | 2019-2023 | Xarelto |
| Acadia Pharmaceuticals INC | $127.62 | 2023-2025 | Daybue |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Avanir Pharmaceuticals, INC. | $124.98 | 2019 | |
| Shield Therapeutics INC | $82.51 | 2023 | Accrufer |
| Sanofi-Aventis U.S. LLC | $58.20 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $54.38 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $50.89 | 2021-2023 | Linzess |
| Horizon Therapeutics Plc | $43.97 | 2022-2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $42.00 | 2019-2020 | |
| Canon Medical Systems USA, INC. | $36.56 | 2022 | |
| Vanda Pharmaceuticals INC. | $36.48 | 2019 | |
| Radius Health, INC. | $33.22 | 2019 | |
| Teleflex LLC | $32.41 | 2025 | Urolift |
| Allergan, INC. | $25.40 | 2020 | |
| Astellas Pharma US INC | $24.93 | 2019 | |
| Eisai INC. | $23.70 | 2020 | |
| Daiichi Sankyo INC. | $23.63 | 2020 | |
| Exact Sciences Corporation | $20.88 | 2024 | Cologuard Collection Kit |
| Optos, INC. | $20.12 | 2021 | |
| Gilead Sciences, INC. | $19.05 | 2020 | |
| Seqirus USA INC | $15.73 | 2019 | |
| Sanofi Pasteur INC. | $15.53 | 2019 | |
| Zealand Pharma US, INC. | $12.19 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.